Exagen Inc.
As of Oct 22, 2026, Exagen is in Stage 2, the uptrend phase, now in week 10 (since Aug 18, 2026). It closed at $7.48, 37.5% below its 52-week high and above its 200-day average, which is rising.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care
Is XGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
XGN among Diagnostics & Research37th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …37 | XGN | Stage 2 · wk 10 | 30 | −12.5% |
Exagen: quick answers
What stage is Exagen in?
As of Oct 22, 2026, Exagen (XGN) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 18, 2026 and is in week 10. What the four stages mean
Is Exagen in an uptrend?
Yes. Exagen is in a Stage 2 uptrend. It trades 50.9% above its 200-day average, which is rising.
How far is Exagen from its 52-week high?
Exagen closed at $7.48 on Oct 22, 2026, 37.5% below its 52-week high of $11.96. Its 52-week low is $2.65.
How has Exagen performed over the past year?
As of Oct 22, 2026, Exagen is down 36.0% over the past year and up 23.8% so far in 2026.
Which sector and industry is Exagen in?
Exagen is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.